associated with CDI-related stays in the hospital were $8.2 billion in the U.S. during 2009. CDI is a rising global HAI problem in which the toxins produced by C. difficile
bacteria result in diarrhea (C. difficile
-associated diarrhea (CDAD)), and in the most serious cases, pseudomembranous colitis (erosion of the lower GI tract) that can lead to death. CDI is a major, unintended risk associated with the prophylactic or therapeutic use of intravenous antibiotics, which may alter the natural balance of microflora that normally protect the GI tract, leading to C. difficile
overgrowth and infection. Other risk factors for CDI include hospitalization, prolonged length of stay, underlying illness, immune-compromising conditions including the administration of chemotherapy, and advanced age.
CDI is a widespread and often drug resistant infectious disease, and it is estimated that 1.1 million patients are infected with C. diff annually in the U.S.* Controlling the spread of CDI has proven challenging, as the C. difficile spores are easily transferred to patients via normal contact with healthcare personnel and other inanimate objects. There is currently no vaccine or approved product for the prevention of C. diff infection.
About Fujifilm Diosynth Biotechnologies (http://www.fujifilmdiosynth.com)
FUJIFILM Diosynth Biotechnologies UK Limited is an industry leading biologics Contract Development and Manufacturing Organization. Fujifilm Diosynth Biotechnologies has extensive experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules expressed in a wide array of microbial, mammalian, and insect systems. The company offers a comprehensive list of services from microbial and mammalian cell line development, including its proprietary pAVEway™ system, to process development, analytical develo
Page: 1 2 3 4 5 Related biology technology :1
|SOURCE Synthetic Biologics, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
. Synthetic DNA Deemed Patentable by US Supreme Court, Gene Synthesis and Codon Optimization Provide Potential Pathway to Patentability2
. Synthetic Biologics to Present at OneMedForum New York 20133
. New England Biolabs supports iGEM synthetic biology competition4
. Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference5
. Intrexon Organizes Around New Synthetic Biology Markets6
. Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives7
. Synthetic Biologics Reiterates that the Infectious Disease Collaboration with Intrexon Remains in Effect8
. Express Genes by Eurofins MWG Operon Offers 4 Day Delivery of Synthetic Genes9
. Top Ten Suppliers of Synthetic Biology Technology10
. Infectious Disease Specialist, Brad Spellberg, M.D., Joins Synthetic Biologics Scientific Advisory Board11
. Discovery in synthetic biology takes us a step closer to new industrial revolution